A Multicenter Retrospective Study on the Clinical Course of Smoldering Multiple Myeloma(SMM) Patients in Asia

A Multicenter Retrospective Study on the Clinical Course of Smoldering Multiple Myeloma(SMM) Patients in Asia - Retrospective Study of SMM in Asia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019059

Enrollment

400

Registered

2015-09-17

Start date

2015-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoldering multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: SMM patients who were diagnosed in seven countries in Asia (Japan, Korea, China, Singapore, Taiwan, Hong Kong, and Thailand) by between January 1, 2004 and December 31, 2013

Exclusion criteria

Exclusion criteria: symptomatic multiple myeloma

Design outcomes

Primary

Measure	Time frame
High-risk factors in Asian SMM patients (The high-risk factor or the combination of high-risk factors that 60% of SMM patients progress for symptomatic myeloma within two years)	—

Secondary

Measure	Time frame
1.Periods from SMM to symptomatic myeloma 2.Progress rate to symptomatic myeloma at two and five years after the diagnosis of SMM 3.Five-year overall survival rate from the diagnosis of SMM 4.Overall survival of SMM	—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactTADAO ISHIDA

Sapporo Medical University School of Medicine Department Gastroenterology, Rheumatology and Clinical Immun

ishidat@sapmed.ac.jp011-611-2111

Outcome results